H. Lundbeck A/S (Lundbeck) strengthens its pipeline of pharmaceuticals in
clinical development by initiating phase I clinical studies with Lu AE04621 in
order to investigate safety, tolerability and the pharmacokinetic profile of the
drug in humans. The placebo-controlled study is expected to enrol around 100
healthy individuals.

Lu AE04621 is a novel agent that acts on the areas of the brain that are
affected in Parkinson's disease with similar net effect as Lu 02-750, which
entered phase I in November 2009. In animal models, the compound has
demonstrated very convincing effects when compared to conventional treatments.
Expectations are that the compound can offer Parkinson's patients a new and
higher level of disease control.

"Our focus at Lundbeck Research is on discovering new innovative treatments that
address unmet needs and offer clear benefits to the patients, and we believe
that Lu AE04621 has the potential to improve the treatment and quality of life
of patients suffering from Parkinson's disease", says Executive Vice President
Peter Høngaard Andersen, Head of Research at Lundbeck, and continues: "The
parallel testing in humans of Lu 02-750 and Lu AE04621 will enable us to select
the most promising compound for further development at an early stage."

About Parkinson's disease
Parkinson's disease is an age-related degenerative disorder of the brain.
Symptoms can include tremor, stiffness, slowness of movement and impaired
balance. An estimated four million people worldwide suffer from the disease,
which usually affects people over the age of 60.


Lundbeck contacts



 Investors:                   Media:



 Jacob Tolstrup               Mads Kronborg

 Director, IR & Communication Media Relations

 +45 36 43 30 79              +45 36 43 28 51



 Palle Holm Olesen            Stine Hove Marsling

 Head of Investor Relations   External Communication Specialist

 +45 36 43 24 26              +45 36 43 28 33



 Magnus Thorstholm Jensen

 Investor Relations Officer

 +45 36 43 38 16



About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical
company highly committed to improve the quality of life for people suffering
from central nervous system (CNS) disorders. For this purpose Lundbeck is
engaged in the research and development, production, marketing and sale of
pharmaceuticals across the world, targeted at disorders like depression and
anxiety, schizophrenia, insomnia, Huntington's, Alzheimer's and Parkinson's
diseases.

Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark, and
employs today over 5,700 people worldwide. Lundbeck is one of the world's
leading pharmaceutical companies working with CNS disorders. In 2009, the
company's revenue was DKK 13.7 billion (approximately EUR 1.8 billion or USD
2.6 billion). For more information, please visit www.lundbeck.com.



[HUG#1400617]





    Release no 400: 

http://hugin.info/130085/R/1400617/355868.pdf